Press release
Neuroendocrine Carcinoma Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Emerging Trends
Neuroendocrine Carcinoma
The growth of targeted therapies is also expected to propel the neuroendocrine carcinoma market. Neuroendocrine carcinoma, a rare and aggressive cancer, benefits from advancements in personalized medicine and the development of treatments targeting specific genetic mutations and molecular pathways. Targeted therapies that focus on the tumor's genetic and biochemical profiles offer better precision and effectiveness. For example, the American Society of Gene & Cell Therapy reported that the number of gene therapies in Phase II clinical trials increased by 5% from Q1 2023 to Q2 2023. This growth in targeted therapies is likely to continue to drive advancements in neuroendocrine carcinoma treatment.
Get Your Neuroendocrine Carcinoma Market Report Here:
https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report
What is the projected compound annual growth rate (CAGR) of the neuroendocrine carcinoma market from 2025 to 2034, and what factors influence it?
The neuroendocrine carcinoma market has expanded strongly, growing from $1.63 billion in 2024 to $1.76 billion in 2025 at a CAGR of 7.7%. Growth has been driven by advancements in imaging technology, a higher incidence of neuroendocrine tumors, increased investments, government initiatives, and growing demand for treatments.
The neuroendocrine carcinoma market is anticipated to expand steadily, reaching $2.33 billion by 2029, with a CAGR of 7.3%. Growth will be driven by the rising incidence of cancer, an increasing number of product approvals, enhanced diagnostic imaging techniques, the advancement of targeted therapies, and greater access to diagnosis and treatment options. Key trends include progress in diagnostic technology, improved imaging solutions, advancements in neuroendocrine tumor management, and developments in targeted therapies and immunotherapies.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp
How are the latest trends influencing the growth of the neuroendocrine carcinoma market?
In the neuroendocrine carcinoma market, companies are focusing on developing targeted radiopharmaceutical therapies to improve treatment precision and patient outcomes. For instance, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, received FDA orphan drug designation for ABD-147, a targeted radiopharmaceutical for neuroendocrine carcinoma. ABD-147 selectively targets tumors expressing the DLL3 protein, which is upregulated in aggressive neuroendocrine cancers, such as small cell lung cancer and large cell neuroendocrine carcinoma. This designation provides significant development advantages, including tax credits and potential market exclusivity, making ABD-147 a promising therapy for these cancers.
What are the major segments of the neuroendocrine carcinoma market and their role in driving growth?
The neuroendocrine carcinoma market covered in this report is segmented -
1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma
2) By Diagnostic Tools: Imaging, Biopsy, Serology
3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers
Subsegments:
1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors
2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors
3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma
4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21229
Which regions are key players in the growth of the neuroendocrine carcinoma market?
North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the key firms paving the way for growth in the neuroendocrine carcinoma market?
Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp
What Is Covered In The Neuroendocrine Carcinoma Global Market Report?
•Market Size Forecast: Examine the neuroendocrine carcinoma market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the neuroendocrine carcinoma market for a structured understanding.
•Key Players Overview: Analyze major players in the neuroendocrine carcinoma market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the neuroendocrine carcinoma market.
•Segment Contributions: Evaluate how different segments drive overall growth in the neuroendocrine carcinoma market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the neuroendocrine carcinoma market.
•Industry Challenges: Identify potential risks and obstacles affecting the neuroendocrine carcinoma market.
•Competitive Landscape: Review strategic developments in the neuroendocrine carcinoma market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuroendocrine Carcinoma Market Forecast 2025-2034: Evaluating Growth Factors, Segments, and Emerging Trends here
News-ID: 3935115 • Views: …
More Releases from The Business Research Company
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for Neuroendocrine
Neuroendocrine Carcinoma Market Massive Growth opportunity Ahead
Introduction
Neuroendocrine carcinoma (NEC) is a rare and aggressive form of cancer that arises from neuroendocrine cells, which are found throughout the body and are responsible for producing hormones. These tumors can occur in various organs, including the lungs, pancreas, liver, and gastrointestinal tract. Due to its often vague and non-specific symptoms, neuroendocrine carcinoma is frequently diagnosed at an advanced stage, making it challenging to treat effectively.
In recent years, however, there…
Rising Neuroendocrine Tumors Fuel Treatment Market Growth Driving Market Acceler …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Neuroendocrine Tumor Treatment Market Size By 2025?
The industry for treating neuroendocrine tumors has witnessed substantial growth in the previous years. The market size is projected to escalate from $2.17 billion in 2024 to $2.4 billion in 2025, with a compound annual growth rate (CAGR)…
Emerging Trends Influencing The Growth Of The Neuroendocrine Tumor Treatment Mar …
The Neuroendocrine Tumor Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Neuroendocrine Tumor Treatment Market Size Expected to Be by 2034?
The market for neuroendocrine tumor treatment has seen a significant expansion in recent years. Projected to grow from a value…
Prominent Neuroendocrine Tumor Treatment Market Trend for 2025: Clinical Trials …
How Are the key drivers contributing to the expansion of the neuroendocrine tumor treatment market?
The neuroendocrine tumor treatment market is forecasted to expand due to the increasing incidence of neuroendocrine tumors. Neuroendocrine tumors, or NETs, are rare growths that begin in neuroendocrine cells, and their treatment is vital to managing the symptoms, controlling the tumor's growth, and applying radiation therapy to destroy the cancerous cells. The American Society of Clinical…
Neuroendocrine Tumor Treatment Market – Forecast to 2026
According to a new market research report published by Global Market Estimates, the Global Neuroendocrine Tumor Treatment Market is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026 at a CAGR value of 5.7% between 2021 to 2026. High prevalence of neuropsychiatric malignancy, awareness regarding early cancer diagnosis, and an increasing number of government initiatives, the neuroendocrine tumor therapy market is expected to rise…
Neuroendocrine Cancer Market: Rising Prevalence of Neuroendocrine Cancer and Gro …
The market report titled ‘Global Neuroendocrine Cancer Market - Size, Share and Forecast (2019 - 2026)’ produced by DataM Intelligence analyses the industry dynamics in this competitive space to provide a comprehensive analysis of the market opportunities.
Neuroendocrine Cancer Market Segmentation Analysis
Total Neuroendocrine Cancer Studies: 2499
By Drug Type
Everolimus
Sunitinib Malate
Lanreotide
Octreotide
Others
Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for the treatment of…
